LOS ANGELES–(BUSINESS WIRE)–The Law Offices of Frank R. Cruz announces an investigation of Tengjun Biotechnology Corp. (“Tengjun” or the “Company”) (OTC: TJBH) on behalf of investors concerning the Company’s possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On September 5, 2023, Tengjun disclosed that its previously issued financial statements for the fiscal year ended December 31, 2022 should “no longer be relied upon due to accounting methodology errors” and that it plans to restate its financial statements by amending its annual report on Form 10-K for the fiscal year ended December 31, 2022 “as soon as reasonably practicable.”
On this news, Tengjun’s share price fell $3.15, or 17.6%, to close at $14.71 per share on September 5, 2023, thereby injuring investors.
Follow us for updates on Twitter: twitter.com/FRC_LAW.
If you purchased Tengjun securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
[email protected]
www.frankcruzlaw.com
